1. Scrip
  2. >>Business

Dr Reddy’s CEO On Payer Dynamics, China Commitment And Disruption

 
• By Anju Ghangurde

Dr Reddy’s CEO tells Scrip in an interview that it isn’t business as usual, in general, in the US, where it is refining its proprietary products strategy to focus on ‘bigger assets’ in the backdrop of the payer environment there. The Indian company is, however, upbeat on plans for China.

GV Prasad
DR REDDY'S CEO G V PRASAD

Dr. Reddy's Laboratories Ltd. (DRL) continues to chisel and recalibrate its operations in the backdrop of a tough business environment in key markets like the US, but the Indian firm also expects to put the pedal to the metal in China, a market where it has had a long-standing base.(Also see "Big Cost Cuts At Dr Reddy’s, US Big Ticket Launch Progress Is Key" - Scrip, 27 July, 2018.)(Also see "India Pharma Firms Eye China, Dr Reddy’s Sees ‘Great Opportunity’ There" - Scrip, 29 October, 2018.)

In an interview with Scrip at the sidelines of the recently concluded India Pharmaceutical Forum in Mumbai, DRL’s co-chair and CEO GV Prasad maintained that only firms that operate in...

More from Business

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

More from Scrip

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.